Search | Clinical Trials Finder

Conditions: LPL Deficiency
Interventions: alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: Peramivir 150 mg, Peramivir 300 mg, Placebo; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 58
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Stanford, California • Torrance, California • Iowa City, Iowa + 7 more

Conditions: Pain, Opioid Use, Androgen Deficiency, Back Pain
Interventions: Testosterone Cypionate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory Papillomatosis
Interventions: INO-3107, CELLECTRA® 2000; Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more

Conditions: Methamphetamine Use Disorder
Interventions: Ketamine, Psychotherapy; Drug · Behavioral
Lead sponsor: Nicky Mehtani, MD, MPH; Other
Eligibility: 18 Years to 69 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francicso, California

Conditions: Migraine Disorders
Interventions: onabotulinumtoxinA; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 21
States / cities: Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 18 more

Conditions: Schizophrenia
Interventions: Brexpiprazole, OPDC-34712; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 2
States / cities: Garden Grove, California • San Diego, California

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: Platysma Prominence
Interventions: OnabotulinumtoxinA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 25
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encino, California + 22 more

Conditions: Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions: 9vHPV Vaccine, mRNA-1273 Vaccine; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 9 Years to 11 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Dapagliflozin 10Mg Tab; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Preterm Birth
Interventions: 17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-Hydroxyprogesterone Caproate 275 mg SC Dose; Drug
Lead sponsor: Steve N. Caritis, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Newark, Delaware • Durham, North Carolina • Winston-Salem, North Carolina + 1 more

Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions: Testosterone cypionate, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1073, mRNA-1010, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 14
States / cities: Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV MAT, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more

Conditions: Seizures
Interventions: Midazolam; Drug
Lead sponsor: U.S. Army Office of the Surgeon General; Federal
Eligibility: 18 Years to 54 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: NVX-Cov2373; Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 30
States / cities: Long Beach, California • Sacramento, California • DeLand, Florida + 26 more

Conditions: Glabellar Frown Lines
Interventions: AI-09, Vehicle; Biological
Lead sponsor: Eirion Therapeutics Inc.; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Boca Raton, Florida • Miami, Florida • New Brighton, Minnesota + 1 more

Conditions: HIV Prevention
Interventions: Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Norfolk, Virginia

Conditions: Kidney Transplant Recipient
Interventions: Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication; Biological · Other
Lead sponsor: Mark Stegall; Other
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: HIV Infections
Interventions: APL 400-047, Bupivacaine hydrochloride; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2001
U.S. locations: 4
States / cities: Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: HIV Infections
Interventions: rAd5 Gag-Pol Env A/B/C, rAd5 Gag-Pol; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Schizophrenia
Interventions: Risperidone ISM 75 mg, Risperidone ISM 100 mg; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more

Search by objective public record fields.

Alipogene Tiparvovec for the Treatment of LPLD Patients

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

Comparison of Delivery Routes of Flu Vaccine in Adults

Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

17-OHPC in Pregnancy: IM vs SC Routes

COMbination of Bipolar Androgen Therapy and Nivolumab

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

AI-09 In Subjects With Glabellar Lines, GL-101

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

Antigenic Competition in HIV Preventive Vaccines

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension